Suchergebnisse

This guideline is the result of a systematic literature review using the 'Grading of Recommendations Assessment, Development and Evaluation' (GRADE) methodology and a structured consensus conference held on 28 and 29 November 2012, in Berlin. It is a joint initiative of the Dermatology Section of the European Academy of Allergy and Clinical Immunology (EAACI), the EU-funded network of excellence, the Global Allergy and Asthma European Network (GA(2)LEN), the European Dermatology Forum (EDF), and the World Allergy Organization (WAO) with the participation of delegates of 21 national and international societies. Urticaria is a frequent, mast cell-driven disease, presenting with wheals, angioedema, or both. the life-time prevalence for acute urticaria is approximately 20%. Chronic spontaneous urticaria and other chronic forms of urticaria do not only cause a decrease in quality of life, but also affect performance at work and school and, as such, are members of the group of severe allergic diseases. This guideline covers the definition and classification of urticaria, taking into account the recent progress in identifying its causes, eliciting factors and pathomechanisms. in addition, it outlines evidence-based diagnostic and therapeutic approaches for the different subtypes of urticaria. This guideline was acknowledged and accepted by the European Union of Medical Specialists (UEMS). ; Charite, Allergy Ctr Charite, Dept Dermatol & Allergy, D-10117 Berlin, Germany ; Med Univ Graz, Dept Dermatol, Graz, Austria ; Clin San Carlo, Allergy Clin, Paderno Dugnano, MI, Italy ; Univ Southern Denmark, Odense Univ Hosp, Dept Dermatol & Allergy Ctr, Odense, Denmark ; Med Univ Silesia, Allergol & Clin Immunol Katowice, Dept Internal Dis, Zabrze, Poland ; Univ Genoa, IRCCS AOU SanMartino, Genoa, Italy ; Universidade Federal de São Paulo, Dept Clin Immunol & Allergy, São Paulo, Brazil ; Univ Autonoma Barcelona, Hosp Mar Parc Salut Mar, E-08193 Barcelona, Spain ; Dr DY Patil Med Coll & Hosp, Dept Dermatol, Navi Mumbai, India ; Fac Med, Dermatol Clin, Coimbra, Portugal ; Univ Hosp, Coimbra, Portugal ; Guys & St Thomas Hosp NHS Fdn Trust, St Johns Inst Dermatol, London, England ; Ctr Appl Res Allergy Quebec, Quebec City, PQ, Canada ; Hiroshima Univ, Inst Biomed & Hlth Sci, Dept Dermatol, Hiroshima, Japan ; Med Univ S Carolina, Dept Med, Div Pulm & Crit Care Med, Charleston, SC USA ; Hannover Med Sch, Dept Dermatol & Allergy, Hannover, Germany ; Pantai Hosp Kuala Lumpur, Dept Paediat, Kuala Lumpur, Malaysia ; Univ Hosp Tenon, Dept Dermatol & Allergy, Paris, France ; Johns Hopkins Asthma & Allergy Ctr, Baltimore, MD USA ; Ctr Medicodocente Trinidad, Allergy & Clin Immunol Dept, Caracas, Venezuela ; Univ Hosp, Dept Dermatol, Allergy Unit, Zurich, Switzerland ; Univ Manitoba, Dept Pediat & Child Hlth, Winnipeg, MB R3T 2N2, Canada ; Univ Manitoba, Dept Immunol, Winnipeg, MB, Canada ; Univ Med Ctr Mainz, Dept Dermatol, Mainz, Germany ; Univ Toronto, Div Allergy & Clin Immunol, Toronto, ON, Canada ; Technion, Fac Med, Bnai Zion Med Ctr, Haifa, Israel ; Univ Bari, Dept Biomed Sci & Human Oncol, Unit Dermatol & Venereol, Bari, Italy ; Peking Univ, Hosp 1, Dept Dermatol, Beijing 100871, Peoples R China ; Universidade Federal de São Paulo, Dept Clin Immunol & Allergy, São Paulo, Brazil ; Web of Science

This methods report describes the process of guideline development in detail. It is the result of a systematic literature review using the 'Grading of Recommendations Assessment, Development and Evaluation' (GRADE) methodology and a structured consensus conference held on 28 and 29 November 2012, in Berlin. It is a joint initiative of the Dermatology Section of the European Academy of Allergy and Clinical Immunology (EAACI), the EU-funded network of excellence, the Global Allergy and Asthma European Network (GA(2)LEN), the European Dermatology Forum (EDF), and the World Allergy Organization (WAO) with the participation of delegates of 21 national and international societies. This guideline covers the definition and classification of urticaria, taking into account the recent progress in identifying its causes, eliciting factors and pathomechanisms. in addition, it outlines evidence-based diagnostic and therapeutic approaches for the different subtypes of urticaria. This guideline was acknowledged and accepted by the European Union of Medical Specialists (UEMS) and is published in Allergy 2014; 69:868-887. ; GA2LEN ; EAACI ; Charite, Allergy Ctr Charite, Dept Dermatol & Allergy, Berlin, Germany ; Med Univ Graz, Dept Dermatol, Graz, Austria ; Clin San Carlo, Allergy Clin, Paderno Dugnano, Italy ; Odense Univ Hosp, Dept Dermatol, DK-5000 Odense, Denmark ; Odense Univ Hosp, Allergy Ctr, DK-5000 Odense, Denmark ; Univ Southern Denmark, Odense, Denmark ; Med Univ Silesia, Allergol & Clin Immunol Katowice, Dept Internal Dis, Katowice, Poland ; Univ Genoa, IRCCS AOU SanMartino, Genoa, Italy ; Universidade Federal de São Paulo, São Paulo, Brazil ; Univ Autonoma Barcelona, Hosp Mar Parc Salut Mar, E-08193 Barcelona, Spain ; Dr DY Patil Med Coll & Hosp, Dept Dermatol, Navi Mumbai, India ; Fac Med, Dermatol Clin, Coimbra, Portugal ; Univ Hosp, Coimbra, Portugal ; Guys & St Thomas Hosp NHS Fdn Trust, St Johns Inst Dermatol, London, England ; Ctr Appl Res Allergy Quebec, Quebec City, PQ, Canada ; Hiroshima Univ, Dept Dermatol, Inst Biomed & Hlth Sci, Hiroshima, Japan ; Med Univ S Carolina, Dept Med, Div Pulm & Crit Care Med, Charleston, SC 29425 USA ; Hannover Med Sch, Dept Dermatol & Allergy, Hannover, Germany ; Pantai Hosp Kuala Lumpur, Dept Paediat, Bangsar, Malaysia ; Univ Hosp Tenon, Dept Dermatol & Allergy, Paris, France ; Johns Hopkins Asthma & Allergy Ctr, Baltimore, MD USA ; Ctr Medicodocente Trinidad, Allergy & Clin Immunol Dept, Caracas, Venezuela ; Univ Hosp, Dept Dermatol, Allergy Unit, Zurich, Switzerland ; Univ Manitoba, Dept Pediat & Child Hlth, Winnipeg, MB R3T 2N2, Canada ; Univ Manitoba, Dept Immunol, Winnipeg, MB, Canada ; Univ Med Ctr Mainz, Dept Dermatol, Mainz, Germany ; Univ Toronto, Div Allergy & Clin Immunol, Toronto, ON, Canada ; Technion, Bnai Zion Med Ctr, Fac Med, Haifa, Israel ; Univ Bari, Dept Biomed Sci & Human Oncol, Unit Dermatol & Venereol, Bari, Italy ; Universidade Federal de São Paulo, São Paulo, Brazil ; Web of Science

This evidence- and consensus-based guideline was developed following the methods recommended by Cochrane and the Grading of Recommendations Assessment, Development and Evaluation (GRADE) working group. The conference was held on 1 December 2016. It is a joint initiative of the Dermatology Section of the European Academy of Allergology and Clinical Immunology (EAACI), the EU-founded network of excellence, the Global Allergy and Asthma European Network (GA²LEN), the European Dermatology Forum (EDF) and the World Allergy Organization (WAO) with the participation of 48 delegates of 42 national and international societies. This guideline was acknowledged and accepted by the European Union of Medical Specialists (UEMS). Urticaria is a frequent, mast cell-driven disease, presenting with wheals, angioedema, or both. The lifetime prevalence for acute urticaria is approximately 20%. Chronic spontaneous urticaria and other chronic forms of urticaria are disabling, impair quality of life and affect performance at work and school. This guideline covers the definition and classification of urticaria, taking into account the recent progress in identifying its causes, eliciting factors and pathomechanisms. In addition, it outlines evidence-based diagnostic and therapeutic approaches for the different subtypes of urticaria.

This update and revision of the international guideline for urticaria was developed following the methods recommended by Cochrane and the Grading of Recommendations Assessment, Development and Evaluation (GRADE) working group. It is a joint initiative of the Dermatology Section of the European Academy of Allergology and Clinical Immunology (EAACI), the Global Allergy and Asthma European Network (GA²LEN) and its Urticaria and Angioedema Centers of Reference and Excellence (UCAREs and ACAREs), the European Dermatology Forum (EDF; EuroGuiDerm), and the Asia Pacific Association of Allergy, Asthma and Clinical Immunology with the participation of 64 delegates of 50 national and international societies and from 31 countries. The consensus conference was held on 3 December 2020. This guideline was acknowledged and accepted by the European Union of Medical Specialists (UEMS). Urticaria is a frequent, mast-cell-driven disease that presents with wheals, angioedema, or both. The lifetime prevalence for acute urticaria is approximately 20%. Chronic urticaria, i.e. chronic spontaneous urticaria and chronic inducible urticaria, is disabling, impairs quality of life, and affects performance at work and school. This updated version of the international guideline for urticaria covers the definition and classification of urticaria and outlines expert-guided and evidence-based diagnostic and therapeutic approaches for the different subtypes of urticaria.